Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Total Liabilities (2016 - 2025)

CytomX Therapeutics' Total Liabilities history spans 12 years, with the latest figure at $52.6 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 56.56% year-over-year to $52.6 million; the TTM value through Dec 2025 reached $52.6 million, down 56.56%, while the annual FY2025 figure was $52.6 million, 56.56% down from the prior year.
  • Total Liabilities reached $52.6 million in Q4 2025 per CTMX's latest filing, up from $50.9 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $353.5 million in Q1 2021 to a low of $50.9 million in Q3 2025.
  • Average Total Liabilities over 5 years is $236.6 million, with a median of $283.3 million recorded in 2023.
  • Peak YoY movement for Total Liabilities: grew 4.18% in 2021, then tumbled 71.04% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $339.9 million in 2021, then increased by 1.99% to $346.6 million in 2022, then fell by 28.1% to $249.2 million in 2023, then plummeted by 51.46% to $121.0 million in 2024, then tumbled by 56.56% to $52.6 million in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Total Liabilities are $52.6 million (Q4 2025), $50.9 million (Q3 2025), and $55.1 million (Q2 2025).